Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and ...

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Apellis Pharma (APLS) stock in focus as the FDA expands the label for its injectable therapy Empaveli to treat rare kidney ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted ...

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

Apellis Pharmaceuticals Inc. investors’ allegations concerning its injectable eye drug, SYFOVRE, were correctly determined a ...

Apellis Pharmaceuticals (Nasdaq: APLS) has received clearance from the American medicines regulator for Empaveli (pegcetacoplan) as the first treatment to reduce proteinuria in patients aged 12 and ...